MeiraGTx Holdings plc: insider trades · United States · SEC (Form 4)

About MeiraGTx Holdings plc

MeiraGTx Holdings plc (NASDAQ: MGTX) is a US-listed genetic medicines company focused on gene therapy and gene regulation platforms. Although the holding company is organized under non-US corporate law, the business has major operating and strategic centers in London and New York and is built around a vertically integrated model that combines discovery, manufacturing, quality control, and clinical development. That integrated structure is a core part of the equity story because it gives MeiraGTx more control over vector production, process development, and potential commercial supply than many early-stage peers. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1735438/000110465926060739/mgtx-20260331x10q.htm?utm_source=openai)) The company was founded to address high-unmet-need diseases with gene-based medicines. Over time, it has evolved from a predominantly ocular gene therapy story into a broader genetic medicines platform. According to its 2025 annual report, MeiraGTx has invested heavily in internal manufacturing capabilities, including facilities for viral vector production, plasmid DNA manufacturing, and advanced quality-control testing. Management emphasizes this in-house infrastructure as a strategic advantage for both clinical execution and future commercialization. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0001735438/000110465926036494/mgtx-20251231x10k.htm?utm_source=openai)) MeiraGTx’s main development programs currently center on four late-stage clinical areas spanning ophthalmology, salivary gland disorders, and neurology. Key assets include bota-vec for X-linked retinitis pigmentosa, AAV-hAQP1 for radiation-induced xerostomia, and AAV-GAD for Parkinson’s disease. The company also continues to develop its riboswitch gene regulation platform, which is designed to enable dose-responsive expression of biologics using oral small molecules and could expand the platform into broader therapeutic categories over time. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0001735438/000110465926036494/mgtx-20251231x10k.htm?utm_source=openai)) In competitive terms, MeiraGTx sits in a highly capital-intensive segment where execution risk remains elevated. Its differentiation comes from the combination of proprietary vector engineering, internal manufacturing scale, and a pipeline that includes both disease-targeted clinical programs and a more ambitious gene regulation platform. However, like most clinical-stage biotech companies, it remains pre-profit and has not yet generated meaningful product revenue, so valuation is driven primarily by clinical data, regulatory milestones, partnership economics, and financing capacity. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0001735438/000110465926036494/mgtx-20251231x10k.htm?utm_source=openai)) Recent developments are especially relevant for investors. In April 2026, MeiraGTx announced an underwritten equity offering of roughly $100 million, which should strengthen near-term funding flexibility. Around the same time, it completed an asset purchase related to an ophthalmology program previously associated with Janssen, further reinforcing the retinal gene therapy franchise. The company’s May 2026 corporate update suggests ongoing progress across its pipeline as it works toward potential late-stage value inflection points and, if successful, future commercial launches in the United States market. ([investors.meiragtx.com](https://investors.meiragtx.com/news-releases/news-release-details/meiragtx-announces-pricing-100-million-offering-ordinary-shares?utm_source=openai))